RBC Capital analyst Gregory Renza lowered the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $26.00 (from $29.00) while maintaining ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE